Bromodomain Inhibitor JQ1 as a Candidate Therapeutic Agent in Malignant Pleural Mesothelioma
Abstract
Malignant pleural mesothelioma (MPM) is a rare tumor that develops from the mesothelial linings of the pleural, pericardial, and peritoneal cavities. The actual risk factor for developing the disease is exposure to asbestos in workplace. Bromodomain and extraterminal (BET) domain proteins are epigenetic signaling agents that associate with acetylated histones and expedite the transcription of target genes. This study investigates whether the small molecule BET protein inhibitor JQ1 specifically may be an effective therapy for MPM. Reverse transcriptase polymerase chain reaction methods reveal an inclusive change in gene expression implying that JQ1 is a potential inhibitor which targets the BET proteins. Our results report that JQ1 has tumor-suppressive effects as it significantly ceased cellular activity in MPM cell lines. We predict that JQ1 may be the promising therapy for pleural mesothelioma cancers.
Downloads
References
B. Kroczynska, R. Cutrone, M. Bocchetta, H. Yang, A. G. Elmishad, P. Vacek, M. Ramos-Nino, B. T. Mossman, H. I. Pass and M. Carbone. Crocidolite asbestos and SV40 are co-carcinogens in human mesothelial cells and in causing mesothelioma in hamsters”. Proc Natl Acad Sci USA vol. 103, pp. 14128-14133, 2006.
B. W. S. Robinson, A. W. Musk and A. Lake. “Malignant mesothelioma”. Lancet, vol. 366, pp. 397-408, 2005.
M. Carbone, B. H. Ly, R. F. Dodson, I. Pagano, P. T. Morris, U. A. Dogan, A. F. Gazdar, H. I. Pass and H. Yang. “Malignant mesothelioma: Facts, myths, and hypotheses”. Journal of Cellular Physiology, vol. 227, pp. 44-58, 2012.
S. Y. Wu, A. Y. Lee, H. T. Lai, H. Zhang and C. M. Chiang. “Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting”. Molecular Cell, vol. 49, pp. 843-857, 2013.
P. Filippakopoulos, S. Picaud, M. Mangos, T. Keates, J. Lambert, D. Barsyte-Lovejoy, I. Felletar, R. Volkmer, S. Muller, T. Pawson, A. Gingras, C. Arrowsmith and S. Knapp. “Histone recognition and large-scale structural analysis of the human bromodomain family”. Cell, vol. 149, pp. 214-231, 2012.
P. Filippakopoulos, J. Qi, S. Picaud, Y. Shen, W. B. Smith, O. Fedorov, E. M. Morse, T. Keates, T. T. Hickman, I. Felletar, M. Philpott, S. Munro, M. R. McKeown, Y. Wang, A. L. Christie, N. West, M. J. Cameron, B. Schwartz, T. D. Heightman, N. La Thangue, C. A. French, O. West, A. L. Kung, S. Knapp and J. E. Bradner. “Selective inhibition of BET bromodomains”. Nature, vol. 468, pp. 1067-1073, 2010.
M. A. Dawson, R. K. Prinjha, A. Dittman, G. Giotopoulos, M. Bantscheff, W. I. Chan, S. C. Robson, C. Chung, C. Hopf, M. M. Savitski, C. Huthmacher, E. Gudgin, D. Lugo, S. Beinke, T. D. Chapman, E. J. Roberts, P. E. Soden, K. R. Auger, O. Mirguet, K. Doehner, R. Delwel, A. K. Burnett, P. Jeffrey, G. Drewes, K. Lee, B. J. Huntly and T. Kouzarides T. “Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia”. Nature, vol. 478, pp. 529-533, 2011.
J. E. Delmore, G. C. Issa, M. E. Lemieux, P. B. Rahl, J. Shi, H. M. Jacobs, E. Kastritis, T. Gilpatrick, R. M. Paranal, J. Qi, M. Chesi, A. Schinzel, M. R. McKeown, T. P. Heffernan, C. R. Vakoc, L. Bergsagel, I. M. Ghobrial, P. G. Richardson, R. A. Young, W. C. Hahn, K. C. Anderson, A. L. Kung, J. E. Bradner and C. S. Mitsiades. “BET bromodomain inhibition as a therapeutic strategy to target c-Myc”. Cell, vol. 146, pp. 904-917, 2011.
J. A. Mertz, A. R. Conery, B. M. Bryant, P. Sandy, S. Balasubramanian, D. A. Mele, L. Bergeron and R. J. Sims. “Targeting MYC dependence in cancer by inhibiting BET bromodomains”. Proc Natl Acad Sci USA, vol. 108, pp. 16669-16674, 2011.
B. C. Christensen, E. A. Houseman, J. J. Godleski, C. J. Marsit, J. L. Longaker, C. R. Roelofs, M. R. Karagas, M. R. Wrensch, R. Yeh, H. H. Nelson, J. L. Wiemels, S. Zheng, J. K. Wiencke, R. Bueno, D. J. Sugarbaker and K. T. Kelsey. “Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome”. Cancer Res, vol. 69, pp. 227-234, 2009.
P. K. Paik and L. M. Krug. “Histone deacetylase inhibitors in malignant pleural mesothelioma preclinical rationale and clinical trials”. J Thorac Oncol, vol. 5, pp. 275-279, 2010.
M. Yun, J. Wu, J. L. Workman and B. Li. “Readers of histone modifications”. Cell Res, vol. 21, pp. 564-578, 2011.
N. Sachini. “The Role of Lysine Acetylation, Histone Acetyltransferases and Bromodomain Containing Proteins in Cancer Development”. Master Thesis, UMC Utrecht, 2013.
V. Janson. “Cisplatin-resistance and Cell Death in Malignant Pleural Mesothelioma Cells”. Doctoral Thesis, Umeå University, 2008.
S. Picaud, D. D. Costa, A. Thanasopoulou, P. Filippakopoulos, P. V. Fish, M. Philpott, O. Fedorov, P. Brennan, M. E. Bunnage, D. R. Owen, J. E. Bradner, P. Taniere, B. O’Sullivan, S. Muller, J. Schwaller, T. Stankovic and S. Knapp. “PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains”. Cancer Res, vol. 73, pp. 3336-3346, 2013.
Copyright (c) 2020 Cinaria T. Albadri
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License [CC BY-NC-ND 4.0] that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).